Back to Search
Start Over
The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis.
- Source :
-
Circulation [Circulation] 2013 Apr 16; Vol. 127 (15), pp. 1609-19. Date of Electronic Publication: 2013 Mar 19. - Publication Year :
- 2013
-
Abstract
- Background: Atherosclerosis is a chronic inflammatory vascular disease driven by the subendothelial accumulation of macrophages. The mechanism regulating the inflammatory response in macrophages during atherogenesis remains unclear. Because microRNAs (miRNAs) play a crucial role in cellular signaling by posttranscriptional regulation of gene expression, we studied the miRNA expression profiles during the progression of atherosclerosis.<br />Methods and Results: Using an miRNA real-time polymerase chain reaction array, we found that macrophage-derived miR-342-5p and miR-155 are selectively upregulated in early atherosclerotic lesions in Apoe(-/-) mice. miR-342-5p directly targets Akt1 through its 3'-untranslated region. Akt1 suppression by miR-342-5p induces proinflammatory mediators such as Nos2 and II6 in macrophages via the upregulation of miR-155. The local application of an miR-342-5p antagomir inhibits the development of atherosclerosis in partially ligated carotid arteries. In atherosclerotic lesions, the miR-342-5p antagomir upregulated Akt1 expression and suppressed the expression of miR-155 and Nos2. This reduced Nos2 expression was associated with a diminished generation of nitrotyrosine in the plaques. Furthermore, systemic treatment with an inhibitor of miR-342-5p reduced the progression of atherosclerosis in the aorta of Apoe(-/-) mice.<br />Conclusions: Macrophage-derived miR-342-5p promotes atherosclerosis and enhances the inflammatory stimulation of macrophages by suppressing the Akt1-mediated inhibition of miR-155 expression. Therefore, targeting miR-342-5p may offer a promising strategy to treat atherosclerotic vascular disease.
- Subjects :
- Animals
Aortic Diseases genetics
Aortic Diseases pathology
Aortic Diseases physiopathology
Apolipoproteins E deficiency
Atherosclerosis genetics
Atherosclerosis physiopathology
Bone Morphogenetic Protein Receptors, Type II biosynthesis
Bone Morphogenetic Protein Receptors, Type II genetics
Carotid Stenosis genetics
Carotid Stenosis pathology
Carotid Stenosis physiopathology
Carotid Stenosis prevention & control
Chemokine CCL2 biosynthesis
Chemokine CCL2 genetics
DEAD-box RNA Helicases deficiency
DEAD-box RNA Helicases genetics
Disease Progression
Interleukin-6 biosynthesis
Interleukin-6 genetics
Macrophages metabolism
Mice
Mice, Knockout
MicroRNAs antagonists & inhibitors
MicroRNAs biosynthesis
MicroRNAs genetics
Nitric Oxide Synthase Type II biosynthesis
Nitric Oxide Synthase Type II genetics
Oligonucleotides pharmacology
Oligonucleotides therapeutic use
RNA, Antisense pharmacology
RNA, Antisense therapeutic use
Ribonuclease III deficiency
Ribonuclease III genetics
Signal Transduction physiology
Tyrosine analogs & derivatives
Tyrosine metabolism
Up-Regulation
Vasculitis genetics
Vasculitis physiopathology
Atherosclerosis pathology
Gene Expression Regulation drug effects
Macrophage Activation
MicroRNAs physiology
Proto-Oncogene Proteins c-akt physiology
Vasculitis pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4539
- Volume :
- 127
- Issue :
- 15
- Database :
- MEDLINE
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 23513069
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.112.000736